What is HC Wainwright’s Estimate for argenex Q2 Earnings?

argenex SE (NASDAQ:ARGX) – Research analysts at HC Wainwright dropped their Q2 2027 earnings per share (EPS) estimates for shares of argenex in a research note issued to investors on Friday, October 23rd. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $7.83 per share for the quarter, down from their prior forecast of $8.41. HC Wainwright has a “Buy” rating and a $1,202.00 price target on the stock. The consensus estimate for argenex’s current full-year earnings is $25.79 per share. HC Wainwright also issued estimates for argenex’s Q3 2027 earnings at $9.39 EPS and Q4 2027 earnings at $9.76 EPS.

Several other research firms also recently weighed in on ARGX. Truist Financial upped their price objective on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Citigroup boosted their target price on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. The Goldman Sachs Group reaffirmed a “buy” rating on shares of argenex in a research report on Friday, September 25th. Wells Fargo & Company cut their price target on argenex from $1,356.00 to $1,336.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Oppenheimer decreased their price objective on argenex from $1,100.00 to $1,038.00 and set an “outperform” rating for the company in a report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,142.37.

argenex Trading Down 0.5%

NASDAQ ARGX opened at $869.33 on Monday. The company has a fifty day simple moving average of $953.35 and a 200 day simple moving average of $853.01. argenex has a 12-month low of $661.85 and a 12-month high of $1,072.75. The company has a market cap of $54.67 billion, a P/E ratio of 30.33, a PEG ratio of 0.89 and a beta of 0.44.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The business had revenue of $1.75 billion for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. increased its position in shares of argenex by 2.7% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 500 shares of the company’s stock valued at $479,000 after purchasing an additional 13 shares during the last quarter. Park Avenue Securities LLC grew its position in argenex by 157.4% during the third quarter. Park Avenue Securities LLC now owns 2,461 shares of the company’s stock valued at $2,360,000 after buying an additional 1,505 shares during the period. Sigma Planning Corp bought a new position in argenex during the third quarter valued at about $1,027,000. Signaturefd LLC grew its position in argenex by 2.6% during the third quarter. Signaturefd LLC now owns 2,129 shares of the company’s stock valued at $2,041,000 after buying an additional 54 shares during the period. Finally, BG Investment Services LLC purchased a new stake in argenex during the third quarter worth about $1,397,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.